TITLE

Lung cancer • 4: Chemotherapy for non-small cell lung cancer: the end of the beginning

AUTHOR(S)
Cullen, M.
PUB. DATE
April 2003
SOURCE
Thorax;Apr2003, Vol. 58 Issue 4, p352
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Charts the development of chemotherapy in non-small cell lung cancer (NSCLC) and discusses its role in advanced disease, as a neoadjuvant therapy before definitive surgery, as an adjuvant after surgery, in subgroups of patients defined by age and performance status, and in patients who relapse after a response to primary chemotherapy. Chemotherapeutic agents; Chemotherapy for elderly patients.
ACCESSION #
10082569

 

Related Articles

  • Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Bennouna, J.; Breton, J.-L.; Tourani, J.-M.; Ottensmeier, C.; O'Brien, M.; Kosmidis, P.; Huat, T. E.; Pinel, M.-C.; Colin, C.; Douillard, J.-Y. // British Journal of Cancer;5/22/2006, Vol. 94 Issue 10, p1383 

    A multicentre, single-arm, phase II trial designed to determine the efficacy of single-agent vinflunine in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum-based regimen. The objectives were to assess efficacy in terms of tumour response rate (primary...

  • Erlotinib prolongs survival of patients with NSCLC.  // Formulary;Nov2004, Vol. 39 Issue 11, p529 

    Reports on a study evaluating the use of the investigational agent erlotinib to treat non-small-cell lung cancer. Survival rates; Safety profile; Treatment outcomes.

  • Gefitinib approved for lung cancer.  // WHO Drug Information;2003, Vol. 17 Issue 2, p102 

    Reports that the U.S. Food and Drug Administration (FDA) has announced the approval of gefitinib tablets as a single agent treatment for patients with advanced non small-cell lung cancer. Approval of gefitinib as a treatment for patients whose cancer has continued to progress despite treatment...

  • Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Hayashi, H.; Okamoto, I.; Morita, S.; Taguri, M.; Nakagawa, K. // Annals of Oncology;Jun2012, Vol. 23 Issue 6, p1537 

    Background: Given the growing number of drugs available for non-small-cell lung cancer (NSCLC), an effect of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies. We examined the relation between postprogression survival (PPS) and OS in phase III trials of...

  • Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. Wada, M.; Yamamoto, M.; Ryuge, S.; Nagashima, Y.; Hayashi, N.; Maki, S.; Otani, S.; Katono, K.; Takakura, A.; Yanaihara, T.; Igawa, S.; Yokoba, M.; Mitsufuji, H.; Kubota, M.; Katagiri, M.; Masuda, N. // Cancer Chemotherapy & Pharmacology;Apr2012, Vol. 69 Issue 4, p1005 

    Background: In this phase II clinical trial, we evaluated the efficacy and safety of S-1 monotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We also measured plasma concentrations of 5-fluorouracil (5-FU) and 5-chloro-2,4-dihydroxypyridine components of...

  • Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Kosmidis, P. A.; Fountzilas, G.; Eleftheraki, A. G.; Kalofonos, H. P.; Pentheroudakis, G.; Skarlos, D.; Dimopoulos, M. A.; Bafaloukos, D.; Pectasides, D.; Samantas, E.; Boukovinas, J.; Lambaki, S.; Katirtzoglou, N.; Bakogiannis, C.; Syrigos, K. N. // Annals of Oncology;Apr2011, Vol. 22 Issue 4, p827 

    Background: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer.Patients and methods:...

  • Schering-Plough loses momentum on anticancer drug, but set to bounce back. Mirasol, Feliza // Chemical Market Reporter;2/16/2004, Vol. 265 Issue 7, p9 

    Reports on pharmaceutical firm Schering-Plough Corp.'s termination of clinical trials of its anticancer drug Sarasar for non-small-cell lung cancer. Reasons of the company for discontinuing trials; Impact of the setback on the company's business outlook.

  • Cell Therapeutics to advance polyglutamate camptothecin to phase II clinical trials.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p12 

    Reports on the announcement of Cell Therapeutics of its plan to begin phase I and II studies of its novel camptothecin polymer conjugate in combination with standard chemotherapy in colorectal cancer and as a single agent in small cell lung cancer, in 2004. Recognition of camptothecin as one of...

  • New drug demonstrates favorable toxicity profile and efficacy in previously treated non-small cell lung cancer patients.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p17 

    Announces that Allos Therapeutics has published results from a clinical study conducted by researchers at the Memorial Sloan-Kettering Cancer Center on PDX as treatment for non-small cell lung cancer. Response rate and symptomatic benefit from the drug.

  • Randomized Trial of Gefitinib for Advanced Lung Cancer Closed Early. Zielinski, Sarah L.; Travis, Kate // JNCI: Journal of the National Cancer Institute;5/18/2005, Vol. 97 Issue 10, p712 

    Reports on Southwest Oncology Group researchers' termination of a phase III randomized clinical trial of gefitinib versus placebo following chemotherapy and radiation for patients with non-small-cell lung cancer that had spread only to nearby tissues or lymph nodes. Number of patients enrolled...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics